Scientists in Japan have developed antibodies that inhibit the gene USAG-1. Following promising results in mice and ferrets, human trials are slated to start in July 2024. A pioneering drug with the potential to regrow teeth will commence human trials early next year.
This revolutionary medication, if proven effective, brings new hope to the countless individuals dependent on dentures.
The Japanese researchers are optimistic that, if successful, the yet-to-be-named treatment could be available to patients by 2030.
Initial studies revealed that the drug stimulated tooth regrowth in mice and ferrets.
The medication is primarily targeted at individuals who are missing a full set of adult teeth due to genetic factors.
Research from two years ago indicated that suppressing the gene USAG-1 using an antibody treatment could stimulate teeth to regrow. Scientists from Kyoto University and the University of Fukui discovered that this antibody treatment solely targets this gene, triggering tooth growth.
On the topic of the upcoming human trial, Dr. Takahashi stated, “The prospect of regrowing new teeth is every dentist’s dream. I’ve been pursuing this since my time as a graduate student.”
Although this treatment might initially benefit a specific group of patients, the scientists believe its applications could expand significantly in the future.
Clinical trials for this antibody treatment, which functions by inhibiting USAG-1, are set to start in July 2024.
The gene USAG-1 restricts tooth growth, as indicated by various studies.
When Kyoto University and the University of Fukui scientists initially discovered this phenomenon in rodents in 2021, they were unsure if merely blocking USAG-1 would be sufficient.
However, their experiments yielded outstanding results.
This method is anticipated to stimulate the growth of a ‘third set’ of teeth in humans, who usually only develop a primary and permanent set of teeth.
Dr. Takahashi conveyed his optimism, stating, “I was certain I could make this a reality. We aim to clear the path for the clinical use of this medication.”
Anodontia, a genetic condition where teeth are missing, affects an unknown percentage of people globally.
As per the Centers for Disease Control and Prevention, over 25 percent of US adults aged 65 or older have eight or fewer teeth.
Current solutions for tooth loss include dentures and other types of artificial tooth replacements. However, these alternatives are often costly, temporary, and not as effective as natural teeth.
